| Literature DB >> 10381498 |
J A Moscow1, H Huang, C Carter, K Hines, J Zujewski, G Cusack, C Chow, D Venzon, B Sorrentino, Y Chiang, B Goldspiel, S Leitman, E J Read, A Abati, M M Gottesman, I Pastan, S Sellers, C Dunbar, K H Cowan.
Abstract
To determine whether the multidrug resistance gene MDR1 could act as a selectable marker in human subjects, we studied engraftment of peripheral blood progenitor cells (PBPCs) transduced with either MDR1 or the bacterial NeoR gene in six breast cancer patients. This study differed from previous MDR1 gene therapy studies in that patients received only PBPCs incubated in retroviral supernatants (no nonmanipulated PBPCs were infused), transduction of PBPCs was supported with autologous bone marrow stroma without additional cytokines, and a control gene (NeoR) was used for comparison with MDR1. Transduced PBPCs were infused after high-dose alkylating agent therapy and before chemotherapy with MDR-substrate drugs. We found that hematopoietic reconstitution can occur using only PBPCs incubated ex vivo, that the MDR1 gene product may play a role in engraftment, and that chemotherapy may selectively expand MDR1 gene-transduced hematopoietic cells relative to NeoR transduced cells in some patients.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10381498
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113